Anaplastic lymphoma kinase tyrosine kinase inhibitor‐induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database

Abstract

What is known and Objective. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors (ALK TKIs) are standard first‐line therapy for non‐small cell lung cancer patients with ALK rearrangement. Although some cases of hepatotoxicity related to these drugs have been reported, there is still a lack of investigation on severe hepatotoxicity, such as hepatic failure, with ALK TKIs. Methods We evaluated ALK TKI (crizotinib, alectinib, brigatinib, ceritinib and lorlatinib)‐induced hepatic failure events (AIHFEs), by using the Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network method for mining the adverse event report signals in the FDA Adverse Event Reporting System (FAERS) database from Jan 2013 to Dec 2019. Results and Discussion The AIHFEs of “Hepatic failure,” “hepatitis fulminant” and “hepatic necrosis” were defined as exposure event signals caused by ALK TKIs. The RORs of “Hepatic failure” were 4.95 (2.36–10.42) in alectinib, 3.77 (1.69–8.40) in ceritinib and 2.45 (1.60–3.76) in crizotinib, respectively. The ROR of “hepatitis fulminant” was 7.86 (3.52–17.54) in crizotinib. The Information Component value of “hepatic necrosis” was 1.97 (0.15) in alectinib. In reports of exposure‐event signals, the clinical outcome of eventual death was common and could occur within 3 months. In the reports of “hepatic failure,” there was no significant difference in the number of reports between men and women [OR=1.86 (0.94–3.67), p = 0.09]. What is new and Conclusions. By mining the adverse event report signals in the FAERS database, we found the exposure event signals of AIHFEs in ALK TKIs were “hepatic failure,” “hepatitis fulminant” and “hepatic necrosis”. AIHFEs were more likely to appear in the reports of ceritinib, crizotinib and alectinib.

Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer

“…6 Fulminant hepatic failure with fatal outcomes has been reported in association with ALK inhibitors. 7 Specifically, alectinib and crizotinib can cause severe elevation of liver enzymes in 5% and 6% of patients, respectively. 8,9 Furthermore, severe elevation of creatine phosphokinase (CPK) can occur in about 4% of patients receiving alectinib.…”